Dogwood Therapeutics (DWTX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DWTX SEC filings page.
This page shows Dogwood Therapeutics, Inc. (DWTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The numbers show a research-heavy business whose financing reshaped the balance sheet while operating losses intensified.
FY2025 R&D spending reached$21.9M while operating cash flow was-$15.6M , showing development spending was the main cash-consuming activity. That spending coincided with a net loss of$34.3M versus$12.3M in FY2024, so accounting deterioration and cash use moved together as the business absorbed development costs.
By FY2025, total liabilities were
The spending mix shifted toward research: R&D was
Financial Health Signals
Dogwood Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Dogwood Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Dogwood Therapeutics, Inc. reported a net loss of $34.3M while operations used $15.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Dogwood Therapeutics, Inc. reported a net loss of $11.5M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Dogwood Therapeutics, Inc. earned -$0.34 per diluted share (EPS) in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Dogwood Therapeutics, Inc. held $9.6M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Dogwood Therapeutics, Inc.'s quarterly ROE was -16.9% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 38.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 10.7 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Dogwood Therapeutics, Inc. invested $3.2M in research and development in Q2 2026. This represents an increase of 26.3% from the same quarter a year earlier. Against the prior quarter it is up 21.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
DWTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $3.2M+26.3% | $2.7M+9.6% | N/A | $14.5M+2613.4% | $2.6M+664.7% | $2.4M+609.0% | N/A | $535K+43.0% |
| SG&A Expenses | $1.6M+20.2% | $2.4M+20.8% | N/A | $1.3M-27.1% | $1.4M+84.4% | $2.0M+105.4% | N/A | $1.8M+96.2% |
| Operating Income | -$14.1Mn/m | -$5.1Mn/m | N/A | -$15.8Mn/m | -$3.9Mn/m | -$4.4Mn/m | N/A | -$2.3Mn/m |
| EBITDA | N/A | N/A | N/A | -$15.8M | -$3.9M | -$4.4M | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $147K | N/A | N/A |
| Net Income | -$11.5Mn/m | -$5.0Mn/m | N/A | -$15.7Mn/m | -$3.8Mn/m | -$10.9Mn/m | N/A | -$2.3Mn/m |
| EPS (Basic) | -$0.34 | -$0.15 | N/A | -$8.20 | -$1.99 | -$8.45 | -$7.57 | -$2.05 |
| EPS (Diluted) | -$0.34 | -$0.15 | N/A | -$8.20 | -$1.99 | -$8.45 | -$7.57 | -$2.05 |
| Diluted Shares (Avg) | 34M | 34M | N/A | 2M | 2M | 1M | N/A | 1M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
DWTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $80.5M-16.8% | $95.2M-1.8% | $90.2M-4.4% | $92.0M+3929.0% | $96.7M+2559.4% | $97.0M+2907.6% | $94.3M+2164.1% | $2.3M-56.5% |
| Current Assets | $11.0M-25.0% | $15.0M-21.7% | $8.4M-49.0% | $11.7M+410.5% | $14.7M+304.4% | $19.2M+494.3% | $16.5M+297.2% | $2.3M-56.5% |
| Cash & Equivalents | $9.6M-28.3% | $13.2M-24.6% | $6.5M-56.1% | $10.1M+396.5% | $13.4M+343.8% | $17.5M+637.1% | $14.8M+347.6% | $2.0M-57.4% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $12.0M-4.0% | $12.2M+3.1% | $12.4M+5.0% | $12.2M | $12.5M | $11.8M | $11.8M | N/A |
| Total Liabilities | $12.1M-86.5% | $14.6M-83.8% | $15.3M-85.4% | $84.7M+6252.8% | $89.8M+17860.1% | $89.9M+15669.2% | $104.4M+29026.5% | $1.3M+173.8% |
| Current Liabilities | $2.8M+50.2% | $2.6M-0.8% | $3.1M-3.7% | $2.6M+94.7% | $1.9M+277.0% | $2.6M+352.5% | $3.2M+785.9% | $1.3M+173.8% |
| Non-Current Liabilities | $9.3M-89.4% | $12.0M-86.2% | $12.2M-87.9% | $82.1Mn/m | $87.9Mn/m | $87.3Mn/m | $101.3Mn/m | $0n/m |
| Total Equity | $68.4M+893.9% | $80.6M+1037.6% | $74.9Mn/m | $7.3M+664.5% | $6.9M+119.4% | $7.1M+167.0% | -$10.1M-365.9% | $949K-80.1% |
| Retained Earnings | -$124.6Mn/m | -$113.1Mn/m | -$108.1Mn/m | -$104.3Mn/m | -$88.6Mn/m | -$84.7Mn/m | -$73.8Mn/m | -$66.1Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
DWTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.6Mn/m | -$4.6Mn/m | -$3.6Mn/m | -$3.3Mn/m | -$4.0Mn/m | -$4.7Mn/m | -$6.1Mn/m | -$910Kn/m |
| Depreciation & Amortization | N/A | N/A | $0 | -$32K | $17K | $17K | N/A | N/A |
| Stock-Based Compensation | N/A | $449K+432.0% | N/A | N/A | N/A | $84K-39.2% | N/A | N/A |
| Financing Cash Flow | $23n/m | $11.3M+53.2% | $33K-99.8% | $0n/m | -$120K | $7.4M | $15.3Mn/m | -$70K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
DWTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -16.9%+38.5pp | -6.2%+148.0pp | N/A | -216.9%+23.3pp | -55.4%-21.9pp | -154.2%-105.5pp | N/A | -240.2%-214.3pp |
| Return on Assets | -14.3%-10.4pp | -5.2%+6.0pp | N/A | -17.1%+82.8pp | -3.9%+24.9pp | -11.3%+28.8pp | N/A | -99.9%-76.4pp |
| Current Ratio | 3.89-3.9x | 5.86-1.6x | 2.76-2.5x | 4.49+2.8x | 7.80+0.5x | 7.43+1.8x | 5.21-6.4x | 1.71-9.1x |
| Liabilities-to-Equity | 0.18-12.9x | 0.18-12.5x | 0.20 | 11.67+10.3x | 13.06+12.9x | 12.69+12.5x | N/A | 1.40+1.3x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Dogwood Therapeutics, Inc. DWTX | FY2025 | N/A | -$34.3M | N/A | $42.2M | — |
| Processa Pharmaceuticals, Inc. PCSA | FY2025 | N/A | -$13.6M | N/A | $5.2M | — |
| TransCode Therapeutics, Inc. RNAZ | FY2025 | N/A | -$34.7M | N/A | $29.5M | — |
| Aprea Therapeutics, Inc. APRE | FY2025 | N/A | -$12.6M | N/A | $6.8M | — |
| AEON Biopharma, Inc. AEON | FY2025 | N/A | N/A | N/A | $15.6M | — |
Where Dogwood Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Dogwood Therapeutics, Inc. profitable?
No, Dogwood Therapeutics, Inc. (DWTX) reported a net loss of $34.3M in fiscal year 2025.
What is Dogwood Therapeutics, Inc.'s EBITDA?
Dogwood Therapeutics, Inc. (DWTX) had EBITDA of -$28.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Dogwood Therapeutics, Inc.'s return on equity (ROE)?
Dogwood Therapeutics, Inc. (DWTX) has a return on equity of -45.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Dogwood Therapeutics, Inc.'s operating cash flow?
Dogwood Therapeutics, Inc. (DWTX) recorded an outflow of $15.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Dogwood Therapeutics, Inc.'s total assets?
Dogwood Therapeutics, Inc. (DWTX) had $90.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Dogwood Therapeutics, Inc. spend on research and development?
Dogwood Therapeutics, Inc. (DWTX) invested $21.9M in research and development during fiscal year 2025.
What is Dogwood Therapeutics, Inc.'s current ratio?
Dogwood Therapeutics, Inc. (DWTX) had a current ratio of 2.76 as of fiscal year 2025, which is generally considered healthy.
What is Dogwood Therapeutics, Inc.'s liabilities-to-equity ratio?
Dogwood Therapeutics, Inc. (DWTX) had a liabilities-to-equity ratio of 0.20 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Dogwood Therapeutics, Inc.'s return on assets (ROA)?
Dogwood Therapeutics, Inc. (DWTX) had a return on assets of -38.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Dogwood Therapeutics, Inc.'s P/E ratio?
Dogwood Therapeutics, Inc. (DWTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $42.2M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Dogwood Therapeutics, Inc.'s price-to-sales ratio?
Dogwood Therapeutics, Inc. (DWTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $42.2M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Dogwood Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Dogwood Therapeutics, Inc. (DWTX) held $6.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.6M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Dogwood Therapeutics, Inc.'s Piotroski F-Score?
Dogwood Therapeutics, Inc. (DWTX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dogwood Therapeutics, Inc.'s earnings high quality?
Dogwood Therapeutics, Inc. (DWTX) reported a net loss of $34.3M while operations used $15.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.